

Supplemental data

Table of content

Supplemental Table 1. Clinical characteristics of patients according to SARS-CoV-2 IgG anti-NC response

Supplemental Table 2. Detailed characteristics of patients with absence of SARS-CoV-2 IgG anti-NC response

Supplemental Table 3. Clinical characteristics of patients with RT-PCR confirmed diagnosis, according to their initial SARS-CoV-2 IgG anti-NC antibody response

Supplemental Table 4. Multivariable analysis of factors associated with the absence of initial SARS-CoV-2 IgG anti-NC antibody response

Supplemental Table 5. Patient characteristics according to their long-term SARS-CoV-2 IgG anti-NC antibody response

Supplemental Table 6. Clinical and biological presentation of patients at diagnosis

Supplemental Figure 1: Evolution of SARS-CoV-2 IgG anti-spike antibody titers until 6 months after diagnosis

Supplemental Table 1. Clinical characteristics of patients according to SARS-CoV-2 IgG anti-NC response

VARIABLE	ALL PATIENTS N = 83	SEROPOS. N = 74	SERONEG. N = 9	P VALUE
Age (years), median (IQR)	65 (19.5)	64 (19.5)	66 (22)	0.274
Male, n (%)	59 (71)	54 (73)	5 (56)	0.427
Cause of nephropathy				0.002
Diabetes and/or vascular nephropathy, n (%)	55 (66)	52 (70)	3 (33)	-
Glomerular disease, n (%)	16 (19)	10 (14)	6 (67)	-
Other, n (%)	12 (14)	12 (16)	0 (0)	-
Time from dialysis initiation (years), median (IQR)	3 (3.8)	3 (3.9)	2 (4.1)	0.584
Comorbidities				
Diabetes mellitus, n (%)	40 (48)	37 (50)	3 (33)	0.485
Hypertension, n (%)	79 (95)	71 (96)	8 (89)	0.374
BMI >25 kg/m ² , n (%)	40/76 (52)	37/68 (54)	3/8 (38)	0.465
Coronary disease, n (%)	21 (25)	17 (23)	4 (44)	0.221
Peripheral artery disease n (%)	28 (34)	24 (32)	4 (44)	0.483
Chronic heart failure	7 (8)	5 (6)	2 (22)	0.165
COPD/asthma	5 (6)	5 (6)	0 (0)	>0.999
Cirrhosis, n (%)	2 (2)	2 (2)	0 (0)	0.569
Cancer, n (%)	5 (6)	5 (7)	0 (0)	0.873
Auto-immune disease, n (%)	6 (7)	2 (3)	4 (44)	0.001
Immunocompromised, n (%)	16 (19)	10 (17)	6 (67)	0.001
Former kidney transplantation, n (%)	6 (7)	5 (6)	1 (11)	0.509
Other organ transplantation, n (%)	1 (11)	1 (13)	0 (0)	>0.999
Immunosuppressive treatment, n (%)	11 (13)	7 (9)	4 (44)	0.016
HIV, n (%)	4 (4)	3 (4)	1 (11)	0.374
RAS inhibitor, n (%)	41 (49)	38 (51)	3 (33)	0.483
ACE inhibitor, n (%)	16 (19)	14 (18)	2 (22)	<0.999
ARB, n (%)	25 (30)	24 (33)	1 (11)	0.264
Characteristics				
Clinical presentation				
Asymptomatic, n (%)	12 (14)	10 (14)	2 (22)	0.612
Mild presentation, n (%)	43 (52)	39 (53)	4 (44)	0.732
Severe presentation, n (%)	28 (34)	25 (34)	3 (33)	>0.999
Hospitalized, n (%)	41 (49)	36 (49)	5 (56)	0.696
Ct-scan (>50% lesions), n (%)	10/37 (26)	9/33 (27)	1/4 (25)	>0.999
RT-PCR diagnosis, n (%)	64/80 (80)	59/71 (83)	5/9 (56)	0.073
First SARS-CoV-2 IgG: value (Index S/C), median (IQR)	5.8 (4.56)	6.5 (3.84)	0.06 (0.14)	<0.0001
Time from diagnosis (days), median (IQR)	67 (39)	68 (41.5)	51 (32.5)	0.11

Specific therapy				
Hydrochloroquine, n (%)	2 (2.5)	2 (2.82)	0 (0)	>0.999
Macrolides, n (%)	14 (16.8)	13 (17.6)	1 (11.1)	>0.999
Convalescent plasma, n (%)	0 (0)	0 (0)	0 (0)	-

Severe or mild presentation was defined according to the need of oxygen therapy. ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker, COPD: chronic obstructive pulmonary disease, HIV: human immunodeficiency virus, RAS: renin angiotensin system

Supplemental table 2. Detailed characteristics of patients with absence of SARS-CoV-2 IgG anti-NC response

PAT.	AGE	SEX	CAUSE OF NEPHROPATHY	TIME FROM DIALYSIS INITIATION (YEARS)	CV RISK FACTOR	VASCU. DISEASE	ORGA N DYSF.	OTHER	IS THERAP Y	DIAG NOSI S	SYMPTOMS	CT-scan	HOSPIT.	THE RAP Y ^{O₂}
P1	63	M	ANCA vasculitis nephropathy	<1	HT ; DM ; smoker ; OW	Y	-	ANCA vasculitis	Steroid ; Cylcophosp hamide	CT-scan	Cough, anosmia, agueusia	severe	Y	Y
P2	66	F	AA amyloidosis	1	HT ; OW	N	-	Rheumatoid arthritis with amyoidosis	Steroid	RT-qPCR	Cough, Fever	moderate	Y	Y
P3	91	M	Vascular	2	HT ; smoker	Y	CHF	-	-	CT-scan	Fever, Dyspnea	mild	Y	Y
P4	74	F	FSGS	1	HT ; DM ; OW	N	-	HIV	-	RT-qPCR	cough	-	N	N
P5	69	M	Diabetic & vascular nephropathy	9	HT ; DM ; smoker	Y	-	-	-	RT-qPCR	UK	-	Y	N
P6	72	F	ANCA vasculitis nephropathy	5	HT	N	-	ANCA vasculitis	MMF	CT-scan	Cough, , Fever	-	Y	Y
P7	28	M	FSGS	<1	-	N	CHF ; COPD	HLH	Steroid ; Etoposide	RT-qPCR	UK	-	N	N
P8	48	M	Glomerular disease	4	HT	N	-	-	-	RT-qPCR	No symptoms	-	N	N
P9	50	F	Glomerular disease	9	HT	Y	-	-	-	CT-scan	No symptoms	Mild	N	N

PAT. : patient; FSGS : Focal and segmental glomerulosclerosis; HT : Hypertension; DM : Diabetes mellitus ; OW :overweight ; CHF : chronic heart failure ; Vasc: vascular ; Dysf. : dysfunction ;HLH: hemophagocytic lymphohistiocytosis; IS :Immunosuppressive ; O₂: Oxygen therapy; Y : yes ; N = : No COPD: chronic obstructive pulmonary disease

Supplemental table 3. Clinical characteristics of patients with RT-PCR confirmed diagnosis, according to their initial SARS-CoV-2 IgG anti-NC antibody response

VARIABLE	ALL PATIENTS N = 64	SEROPOS. N = 59	SERONEG. N = 5	P VALUE
Age (years), median (IQR)	65 (21)	65 (22)	66 (33.5)	0.563
Male, n (%)	49 (78)	46 (78)	3 (60)	0.583
Cause of nephropathy				0.093
Diabetes and/or vascular nephropathy, n (%)	41 (64)	39 (66)	2 (40)	-
Glomerular disease, n (%)	12 (19)	9 (15)	3 (60)	-
Other, n (%)	11 (17)	11 (19)	0 (0)	-
Time from dialysis initiation (years), median (IQR)	3 (4)	3 (4.1)	1.2 (2.2)	0.07
Comorbidities				
Diabetes mellitus, n (%)	32 (50)	30 (51)	2 (40)	>0.999
Hypertension, n (%)	61 (95)	57 (97)	4 (80)	0.220
BMI >25 kg/m ² , n (%)	31/58 (53)	29/53 (55)	2/5 (40)	0.656
Coronary disease, n (%)	15 (23)	14 (24)	1 (20)	>0.999
Peripheral artery disease, n (%)	22 (34)	21 (36)	1 (20)	0.652
Chronic heart failure	6 (9)	5 (8)	1 (20)	0.399
COPD/asthma	5 (8)	5 (8)	0 (0)	>0.999
Cirrhosis, n (%)	2 (3)	2 (3)	0 (0)	>0.999
Cancer, n (%)	4 (6)	4 (7)	0 (0)	>0.999
Auto-immune disease, n (%)	4 (6)	2 (3)	2 (40)	0.028
Immunocompromised, n (%)	12 (19)	9 (15)	3 (60)	0.042
Former kidney transplantation, n (%)	4 (6)	4 (7)	0 (0)	>0.999
Other organ transplantation, n (%)	1 (2)	1 (2)	0 (0)	>0.999
Immunosuppressive treatment, n (%)	9 (14)	7 (12)	2 (40)	0.141
HIV, n (%)	4 (6)	3 (5)	1 (20)	0.284
RAS inhibitor, n (%)	31 (48)	29 (49)	2 (40)	>0.999
ACE inhibitor, n (%)	11 (17)	10 (17)	1 (20)	>0.999
ARBS, n (%)	20 (32)	19 (33)	1 (20)	>0.999
Characteristics, n (%)				
Clinical presentation				
Asymptomatic, n (%)	8 (13)	7 (12)	1 (20)	0.499
Mild, n (%)	33 (52)	30 (51)	3 (60)	>0.999
Severe, n (%)	23 (36)	22 (37)	1 (20)	0.646
Hospitalized, n (%)	34 (53)	32 (54)	2 (40)	0.659

Severe or mild presentation was defined according to the need of oxygen therapy. ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker, COPD: chronic obstructive pulmonary disease, HIV: human immunodeficiency virus, RAS: renin angiotensin system

Supplemental Table 4. Multivariable analysis of factors associated with the absence of initial SARS-CoV-2 IgG anti-NC antibody response

VARIABLE	OR (95%CI)	P VALUE
Chronic heart failure		
No	Ref.	
Yes	7.551 (0.920-61.966)	0.060
Immunocompromised status		
No	Ref.	
Yes	13.8 (2.763-69.126)	0.001

Supplemental Table 5. Patient characteristics according to their long-term SARS-CoV-2 IgG anti-NC antibody response

VARIABLE	ALL PATIENTS N = 60	SEROPOS. N = 45	SERONEG. N = 15	P VALUE
Age (years), median (IQR)	63 (18)	63 (15)	63 (20)	0.925
Male, n (%)	43 (72)	34 (76)	9 (60)	0.324
Cause of nephropathy				
Diabetes and/or vascular nephropathy, n (%)	43 (72)	31 (68)	12 (80)	0.806
Glomerular disease, n (%)	9 (15)	7 (16)	2 (13)	-
Other, n (%)	8 (13)	7 (16)	1 (7)	-
Time from dialysis initiation (years), median (IQR)	3 (3.3)	3.3 (3.2)	2.1 (3.4)	0.522
Comorbidities				
Diabetes mellitus, n (%)	30 (50)	21 (47)	9 (60)	0.371
Hypertension, n (%)	59 (98)	44 (97)	15 (100)	>0.999
BMI >25 kg/m ² , n(%)	32 (59)	24 (57)	8 (60)	>0.999
Coronary disease, n (%)	12 (20)	9 (20)	3 (20)	>0.999
Peripheral artery disease n (%)	18 (31)	11 (24)	7 (47)	0.192
Chronic heart failure	3 (5)	3 (7)	0 (0)	0.566
COPD/asthma	3 (5)	2 (4)	1 (7)	>0.999
Cirrhosis, n (%)	2 (3)	1 (2)	1 (7)	>0.999
Cancer, n (%)	4 (6)	3 (7)	1 (7)	>0.999
Auto-immune disease, n (%)	1 (1)	1 (2)	0 (0)	>0.999
Immunocompromised, n (%)	7 (12)	4 (9)	3 (20)	0.351
Former kidney transplantation, n (%)	3 (5)	1 (2)	2 (13)	0.151
Other organ transplantation, n (%)	1 (11)	1 (13)	0 (0)	>0.999
Immunosuppressive treatment, n (%)	4 (7)	3 (7)	1 (7)	>0.999
HIV, n (%)	3 (5)	2 (4)	1 (7)	>0.999
RAS inhibitor, n (%)	34 (57)	26 (58)	8 (53)	0.764
ACE inhibitor, n (%)	12 (20)	8 (17)	4 (27)	0.479
ARB, n (%)	22 (37)	18 (41)	4 (27)	0.325
Characteristics				
Clinical presentation				
Asymptomatic, n (%)	9 (15)	6 (13)	3 (20)	0.678
Mild, n (%)	33 (55)	24 (53)	9 (53)	0.768
Severe, n (%)	18 (30)	15 (33)	3 (20)	0.517
Hospitalized, n (%)	26 (43)	21 (47)	5 (33)	0.367
IgG pic value (Index S/C), median (IQR)	6.7 (3.8)	7.1 (2.3)	3.44 (1.6)	<0.0001
Time from diagnosis(days), median (IQR)	70.5 (54)	71 (68)	70 (35)	0.323
Last follow up				
IgG value (Index S/C), at last Fup, median (IQR)	3.240 (3.79)	4.02 (3.05)	0.97 (0.68)	<0.0001
Time from diagnosis (days), median (IQR)	189.5 (14.8)	189 (15)	190 (9)	0.764

Severe or mild presentation was defined according to the need of oxygen therapy. ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker, COPD: chronic obstructive pulmonary disease, HIV: human immunodeficiency virus, RAS: renin angiotensin system, Fup : Follow up

Supplemental Table 6. Clinical and biological presentation of patients at diagnosis

	ALL PATIENTS N = 83
Clinical presentation	
Asymptomatic, n (%)	12 (14.4)
Fever, n (%)	39 (46.9)
Dyspnea, n (%)	16 (19.2)
Fatigue, n (%)	31 (37.3)
Flu-like symptoms, n (%)	36 (43.3)
Diarrhea, n (%)	12 (14.4)
Anosmia, n (%)	2 (2.40)
Time from symptoms onset (days), median (IQR)	2 (4.5)
Biological presentation	
C-reactive protein (g/l), median (IQR)	57.5 (106.9)
Procalcitonin (ng/ml), median (IQR)	1.3 (2.2)
Hemoglobin (g/dl), median (IQR)	10.25 (2.3)
Leucocytes (G/l), median (IQR)	4.7 (3)
Lymphocytes (G/l), median (IQR)	0.796 (0.71)
Severity assessment	
Oxygen therapy, n (%)	28 (34)
Hospitalization, n (%)	41 (49)

